This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Shares of Disc Medicine Inc. (NASDAQ:IRON) were trading at $56.94, up $9.81, or 20%, after the firm disclosed positive feedback from its end-of-phase II meeting with the FDA, supporting the regulatory ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

Biogen (NASDAQ:BIIB) shares slid around 3% Thursday after Morgan Stanley analysts downgraded the stock from Overweight to ...

Morgan Stanley analyst Terence Flynn downgraded Biogen (BIIB) to Equal Weight from Overweight with a price target of $204, down from $285. The ...

Q3 2024 Earnings Call Transcript October 30, 2024 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $3.77. Operator: Good morning. My name is Cynthia, and I will be ...

It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were presented ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. | All told, third-quarter U.S. Leqembi sales grew 33% over the prior quarter to $39 ...